April 27, 2018 09:29 AM EDT
R&D
China
Pharma

Ahead of Hong Kong list­ing changes, WuXi preps for a biotech boom with a new R&D cen­ter in Shang­hai

Amber Tong

Bet­ting on the biotech boom that’s now fo­cus­ing con­sid­er­able at­ten­tion on Chi­na, WuXi AppTec has dou­bled down on its in­vest­ment in one of its Shang­hai …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Am­gen’s once-a-month obe­si­ty shot shows 20% weight loss af­ter a year

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

A service from the Financial Times